ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag antibiotic resistance neuroscience disease medicine evolution

Haydeh Payami is wearing a purple dress and an orange and pink scarf and standing in front of a whiteboard.
A Microbial Link to Parkinson’s Disease
Mariella Bodemeier Loayza Careaga, PhD | Dec 4, 2023 | 6 min read
Haydeh Payami helped uncover the genetic basis of Parkinson’s disease. Now, she hopes to find new ways to treat the disease by studying the gut microbiome.
Glowing red DNA on bluish background
Redesigning Medicine Using Synthetic Biology
Alison Halliday, PhD, Technology Networks | Jun 21, 2023 | 5 min read
Drawing inspiration from nature, synthetic biology offers exciting opportunities to transform the future of medicine.
bacteria and DNA molecules on a purple background.
Engineering the Microbiome: CRISPR Leads the Way
Mariella Bodemeier Loayza Careaga, PhD | Mar 15, 2024 | 10+ min read
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
Antibiotics in the Animals We Eat
Bonnie M. Marshall and Stuart B. Levy | Apr 1, 2012 | 3 min read
Low-dose antibiotics in animal feed fuel drug-resistance in human infectious diseases.
Doctors’ Advice to Finish Antibiotics Overlooks Resistance
Abby Olena, PhD | Aug 11, 2017 | 4 min read
There is little evidence that full treatment durations discourage the development of drug-resistant bacteria.
3D multicolored conceptual image representing hallucinogens and the human brain.
Natural High: Endogenous Psychedelics in the Gut and Brain
Iris Kulbatski, PhD | Sep 8, 2023 | 8 min read
Psychedelics are evolutionarily ancient compounds produced by fungi, plants, and microbes. Humans also synthesize psychedelics. Researchers want to know how and why.
antibiotics antibiotics resistance persister bacteria bacteriophage
Opinion: We Need More than New Antibiotics to Fight Resistance
Neil S. Greenspan and Arturo Casadevall | Nov 1, 2019 | 3 min read
Metabolic disrupters, phages, and other approaches are going to be needed to treat the broadest possible range of patients infected by bacterial pathogens resistant to multiple drugs.
3D image of a neuron cell network with a red glow representing inflammation.
New Insight into Brain Inflammation Inspires New Hope for Epilepsy Treatment 
Deanna MacNeil, PhD | Jun 1, 2023 | 2 min read
Clinicians and researchers teamed up to investigate how inappropriate proinflammatory mechanisms contribute to the pathogenesis of drug-refractory epilepsy.
Companies Seeking Solutions To Emerging Drug Resistance
Stephen Hoffert | Apr 12, 1998 | 10 min read
PHASE III NEARS: Cubist Pharmaceuticals has a promising antibiotic--daptomycin--that the company hopes to have in Phase III clinical trials in late 1998 or early 1999. Bacteria are back. Following the discovery and introduction into medicine of penicillin in 1941, intense research in microbiology produced a potent armament of antibiotics that all but eliminated a variety of infectious diseases. With this success, many large pharmaceutical companies scaled back research and development of new
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.

Run a Search

ADVERTISEMENT